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Sundowning means the emergence or worsening of neuropsychiatric symptoms (NPS) 
in the late afternoon or early evening. This syndrome has been recognized since a long 
time in the field of dementing illnesses and is well known among most of health-care 
providers involved in the assistance of people with dementia. Indeed, it represents a 
common manifestation among persons with dementia and is associated with several 
adverse outcomes (such as institutionalization, faster cognitive worsening, and greater 
caregiver burden). Its occurrence and phenotypic characteristics may be influenced 
by diverse neurobiological, psychosocial, and environmental determinants. Moreover, 
it may pose diagnostic challenges in relation to other common causes of behavioral 
disruptions. Beside these considerations, this phenomenon has so far drawn limited 
clinical and scientific interest compared to other specific NPS occurring in dementias, 
as indicated by the lack of commonly agreed definitions, specific screening/assessment 
tools, and robust estimates on its prevalence. Accordingly, no randomized controlled trial 
specifically investigating the effectiveness of pharmacological and non-pharmacological 
strategies in managing this condition among demented patients has been yet conducted. 
In the present narrative review, we present and discuss available evidence concerning 
sundowning occurring in people with dementia. A special focus is given to its definitions, 
pathophysiological determinants, and clinical relevance, as well as to the clinical and 
therapeutic approaches required for its management in the daily practice.
Keywords: sundowning, sundown syndrome, behavioral disruptions, neuropsychiatric symptoms, dementia, 
behavioral and psychological symptoms of dementia, circadian rhythm
inTRODUCTiOn
Neuropsychiatric symptoms (NPS) represent core features of dementias, occurring in the overwhelm-
ing majority of cases and being highly burdening for patients and families. Moreover, they constitute 
a major determinant for health-care expenditures (1, 2). The clinical and research approach to these 
manifestations is extremely challenging. Indeed, NPS are characterized by a marked interindividual 
variability. Their prevalence and severity change over the course of the disease. Moreover, multiple 
interacting variables and pathophysiological mechanisms may influence their occurrence and phe-
notypic expression (3). These aspects have been frequently hindering the application of standardized 
clinical and analytic approaches to NPS, as well as the identification of targeted pharmacological 
interventions (4).
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A condition that properly mirrors the relevant complexity of 
the neuropsychiatric manifestations of dementia is represented 
by the “sundown syndrome,” that is, the emergence or worsening 
of NPS in the late afternoon or early evening. This entity has been 
recognized since a long time in the field of dementing illnesses (5) 
and is well known among most of health-care providers involved 
in the assistance of persons with dementia. Curiously, even many 
ordinary people who have personal experiences or acquired 
knowledge about neurodegenerative diseases are aware of this 
“bizarre” phenomenon. Nevertheless, the sundown syndrome 
has so far drawn limited clinical and scientific interest compared 
to other specific NPS and behavioral disturbances occurring in 
dementias (e.g., apathy, depression, psychotic symptoms). As 
a proof, the available data concerning its prevalence (mostly 
obtained in institutional/residential settings) are scarce and 
markedly discordant in the literature. Moreover, no randomized 
controlled trial (RCT) specifically investigating the effective-
ness of pharmacological and non-pharmacological strategies in 
managing this condition among demented patients has been yet 
conducted. Several aspects may account for this low attention, 
such as the lack of commonly agreed definitions, the absence of 
specific screening and assessment tools and the multiplicity of 
factors that may trigger or affect its occurrence.
In the present narrative review, we present and discuss the 
evidence collected so far concerning the clinical characteristics 
and relevance of the sundown syndrome, its pathophysiological 
determinants and its pharmacological and non-pharmacological 
management. Special attention will be also dedicated to the 
methodological issues that are still limiting and hampering the 
clinical and research approach to this phenomenon.
DeFiniTiOn OF SUnDOwninG
A clear and univocal definition of the sundown syndrome (often 
referred to as “sundowning”) has not been yet achieved. These 
terms are broadly used to describe a set of NPS occurring in 
elderly patients at and/or after the time of sunset. Diverse concep-
tual aspects have hampered the formulation of a unique defini-
tion. First of all, some authors have restricted the adoption of 
the sundowning construct to only people with dementia, whereas 
others have described this phenomenon also among cognitively 
intact elderly individuals (even if with lower frequency) (6). 
A second element of heterogeneity relies in the clinical manifesta-
tions included in the sundown syndrome. Indeed, some defini-
tions refer to the onset or worsening of specific NPS [agitation in 
particular (7)], while others more widely include any behavioral 
and psychological disturbance. In this regard, these behaviors 
may consist of a wide variety of symptoms such as anxiety, 
agitation, aggression, pacing, wandering, resistance, screaming, 
yelling, visual and auditory hallucinations, and so forth (8). 
Several conceptualizations also incorporate the exacerbation of 
cognitive symptoms and confusion (7), thus rendering more sub-
tle the distinction with delirium. Finally, a relevant disagreement 
concerns the timeframe when increased symptoms should occur 
to configure a sundowning. Most of available definitions include 
only the occurrence or worsening of behavioral disturbances dur-
ing the late afternoon and early evening (9, 10), whereas other 
researchers also consider NPS occurring throughout the night 
(11) or more vaguely emerging with darkness (12). It is notewor-
thy that some authors even question the existence of the sundown 
syndrome, hypothesizing that symptoms occurring during the 
entire day may simply be more burdening for nursing staff and 
caregivers in late afternoon and evening (13).
As result of the lack of consensus around the definition of 
sundowning, differently from other neuropsychiatric syndromes 
occurring among elderly individuals (e.g., delirium), no stand-
ardized criteria have been formulated for its diagnosis [e.g., the 
sundown syndrome does not appear in the recent fifth revision of 
the Diagnostic and Statistical Manual of Mental Disorders (14)].
ReLevAnCe OF SUnDOwninG
Beyond the above-mentioned need of agreed definitions, 
sundowning is a relevant clinical phenomenon. First of all, it 
represents a common manifestation among people with demen-
tia. The available studies on the topic have reported prevalence 
rates widely ranging between 2.5% and 66% depending on the 
study setting, the adopted operationalizations, and the underly-
ing clinical diseases (6, 15). Sundowning has been observed to 
represent the second most common type of disruptive behavior in 
institutionalized patients with dementia after wandering and has 
been frequently described as “endemic” in nursing homes hosting 
cognitively impaired older subjects (8, 16). At the same time, it 
has also been commonly described among community-dwelling 
individuals with dementing illnesses [e.g., in the 66% of patients 
with Alzheimer’s disease (AD) living at home (17)]. Based on the 
data from the Alzheimer’s Association, as many as 20% of patients 
diagnosed with AD may experience a sundown syndrome (18). 
This phenomenon has been also reported in the context of 
non-AD dementias (e.g., vascular dementias, frontotemporal 
dementias, Lewy body dementias). Nevertheless, the scarcity 
of epidemiological data does not allow to properly explore the 
different prevalence of sundowning in the specific dementia 
conditions. Along the same lines, there are no consistent data 
concerning its prevalence according to the age, sex, and race of 
patients, whereas the severity of cognitive impairment has been 
repeatedly recognized as important predisposing factor in its 
development (7, 8). Finally, some data suggest a different seasonal 
occurrence of sundowning, with an observed higher incidence in 
the fall or winter months (10).
The relevance of the sundown syndrome also relies on its 
association with several adverse outcomes among people with 
dementia and their families. Sundowning has been indicated 
as a common cause of institutionalization of older demented 
patients. It poses a significant social and economic burden in 
terms of recurrent hospitalizations, prolonged hospital stay, and 
functional decline (1, 15), and it has also been associated with 
a faster progression of cognitive worsening in AD (19). Moreover, 
a relationship between its occurrence and the perceived stress of 
caregivers assisting AD patients has been demonstrated (17). 
Behavioral disruptions in the late afternoon or in the evening 
may pose a further specific challenge to caregivers who have 
to handle such symptoms at the end of the day, when they may 
be particularly fatigued. Some sundown behaviors may prevent 
TAbLe 1 | Factors that have been associated with the pathophysiology 
and clinical occurrence of sundowning among persons with dementia.
Neurobiological factors Degeneration of the suprachiasmatic nucleus
Decreased melatonin production
Disruption of circadian rhythms
Impaired cholinergic neurotransmission
Dysregulation of the HPA axis
Pharmacological factors Antipsychotics
Anticholinergics
Antidepressants
Hypnotics
Physiological factors Fatigue
Hunger
Unmet physical or psychological needs
Temporal changes in body temperature
Circadian modifications of blood glucose levels 
Circadian changes in blood pressure
Medical factors Sleep disorders
Sensory deprivation
Pain
Mood disorders and fluctuations
Cognitive deficits (e.g., agnosia)
Environmental factors Exposure to inadequate amount of light
Lower staff–patients ratio in residential facilities
Lessened availability of home caregivers
Caregiver fatigue
Environmental overstimulation (noise and chaos)
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patients from sleeping well, making them more likely to wander, 
thus increasing the risk for caregiver sleepiness and burnout 
(20, 21). A “stressed caring” of a burdened and fatigued caregiver 
may, in turn, lead to act wrong management strategies and 
increase the likelihood of an exacerbation of NPS exhibited by 
the patient, thus triggering a potential dangerous loop (22).
Based on these considerations, there is a growing consensus 
around the need of achieving a better understanding of sundown-
ing and developing effective strategies for its management.
PATHOPHYSiOLOGY OF SUnDOwninG
The pathophysiology of sundowning is, to date, poorly defined 
since no causative factor has been clearly identified. Nevertheless, 
several hypotheses have been proposed in order to explain this 
phenomenon. Overall, the current conception of the sundown 
syndrome is that of a multifactorial phenomenon, with multiple 
and interacting factors (resumed in Table 1) contributing to its 
occurrence and main phenotypic characteristics.
Under a neurobiological perspective, a large body of evi-
dence, from both animal (23) and human studies (24, 25), has 
been focused on the pathogenic role of primary alterations of 
the normal circadian rhythm (15). Circadian rhythm disorders 
have been linked with the involvement/alteration of the supra-
chiasmatic nucleus (SCN), located in the hypothalamus and 
considered as the major circadian pacemaker of the human body. 
Several studies have shown that volume, morphology, and activ-
ity of the SCN may be influenced by several factors, such as age, 
gender, and pathological conditions. A decrease in cell number 
and volume of the nucleus has been documented within the 
physiological aging process, especially between 80 and 100 years 
of age, as well as in patients with various neurodegenerative 
diseases (26). Neuropathological studies on AD patients have, in 
fact, documented relevant damages involving the SCN, mostly 
consisting of neuronal loss and accumulation of neurofibrillary 
tangles (27), while amyloid plaques are more rarely observed. The 
SCN of individuals with severe AD is also characterized by reac-
tive gliosis in response to neuronal loss, with an increase in the 
astrocyte/neuron ratio. This damage involves both neurotensin 
and vasopressin neurons (26, 28). It has been thus hypothesized 
that sundowning (and other disruptive behaviors) may be the 
result of specific neuropathological abnormalities that interfere 
with normal circadian rhythm and behavioral regulation. 
An important component of circadian rhythm regulation is 
melatonin, a hormone secreted by the pineal gland in response to 
darkness, whose production and release is regulated by the SCN 
itself. Melatonin levels have been shown to decrease during aging 
and to be even more reduced in AD and other neurodegenera-
tive diseases (29, 30). These findings have provided the rationale 
for the supplementation of melatonin in patients with clinical 
manifestations of disrupted sleep and circadian rhythm (31). The 
degeneration of the cholinergic system has also been indicated as 
a potential underlying mechanism of sundowning in AD. In fact, 
it has been demonstrated that the SCN receive several cholinergic 
projections arising from the cholinergic forebrain and brain 
stem nuclei. Moreover, it is sensitive to cholinergic stimulation 
as demonstrated by the expression of muscarinic acetylcholine 
receptors both in SCN neurons and astroglial cells (32). Thus, it 
may be hypothesized that the impaired cholinergic transmission 
may contribute to the disruption of circadian rhythms and the 
emergence of behavioral disturbances. Finally, dysregulations of 
the hypothalamic–pituitary–adrenal axis have been related to the 
pathogenesis of sundowning in AD. Specifically, patients with AD 
exhibiting a sundown syndrome were shown to have significantly 
higher cortisol levels than those without sundowning (33).
Diverse environmental determinants may contribute to the 
onset of sundowning. In particular, a lessened light exposure 
during the day, the reduced availability of caregivers or nursing 
staff members during late afternoon and evening, afternoon 
fatigue (e.g., due to intense activity during the day), the absence 
of a daily routine have been all associated with an overall wors-
ening of NPS and the emergence of a sundown syndrome (8, 
9, 34). In parallel, various medical conditions (e.g., pain, visual 
and/or hearing impairment, mood disorders) and medications 
(e.g., antidepressants, antipsychotics, dopaminergic therapies) 
may induce or exacerbate evening agitation and other behavioral 
disruptions (8, 15).
CLiniCAL APPROACH TO SUnDOwninG
Given the multiplicity of factors and determinants potentially 
involved in the emergence of sundowning, a multidimensional 
approach to this syndrome should be adopted. In particular, 
special attention should be devoted to the identification of 
potentially treatable/reversible underlying conditions in order to 
timely implement targeted interventions. As already proposed for 
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other NPS, integrated, multistep approaches (4, 35, 36) should 
be adopted in screening, identifying, and managing sundowning.
In most of cases, the occurrence of sundowning is easily 
established through direct observation of patients (when insti-
tutionalized) or interviews to caregivers. History taking should 
be followed by a general physical examination, which should 
mostly be finalized at determining the presence of potentially 
contributing/precipitating somatic conditions (e.g., pain, sensory 
deprivation). Accordingly, a careful evaluation of potential envi-
ronmental (e.g., lighting, noise levels, changes in daily routine) 
and iatrogenic triggers should be carried out. The diagnosis of 
sundowning is, thus, essentially clinical. Laboratory tests and 
neuroimaging studies may be performed when other causes of 
behavioral disruptions are suspected (e.g., delirium, cerebro-
vascular events). However, temporal fluctuations and patterns 
of symptoms, their recurrence over time, and non-acute onset 
should direct toward a diagnosis of a sundown syndrome (8). 
Moreover, the adoption of simple yet effective screening tools may 
support the differential diagnosis toward delirium (37). In some 
studies, computer devices have also been adopted to measure and 
quantify the diverse clinical manifestations among “sundowners” 
(e.g., locomotor activity, vocalizations) (38, 39). However, the use 
of such instruments appears difficult to be transferred in the daily 
clinical practice.
It is noteworthy that, to date, no dedicated tools to screen/
assess sundowning has been developed and validated. Moreover, 
in most of clinical tools commonly adopted in the daily practice 
to assess the severity of NPS [e.g., the Neuropsychiatric Inventory 
(40)], the temporal fluctuations of disturbances are poorly con-
sidered, so that indirect information about the eventual occur-
rence of sundowning could not be easily deduced. The adoption 
of standardized instruments to evaluate NPS may also introduce 
some biases, being the results, and scores potentially influenced 
by the personal characteristics of the interviewed caregiver and 
poorly reliable when such tools are administered by different 
raters. These aspects may have probably contributed to the 
poor attention so far devoted to this syndrome and might have 
potentially produced under-recognition of the phenomenon in 
the clinical setting (especially among outpatients with dementia).
MAnAGeMenT OF SUnDOwninG
The management of sundowning represents a challenge in the 
clinical approach of people with dementia. First, the temporal 
fluctuations of symptoms as well as the heterogeneity of potential 
triggers/precipitants may complicate the identification and 
implementation of targeted and personalized interventions. 
Moreover, there are currently neither available guidelines nor 
placebo-controlled randomized trials concerning the treatment 
of such behavioral syndrome. Most of the available data come 
from case series or isolated case reports that, in most of cases, 
do not describe the medium- and long-term effectiveness of the 
adopted treatments. The treatment of sundowning may rely on 
the use of off-label pharmacological treatments, whose efficacy 
and safety profiles are still questioned and debated (4), and may 
result in polypharmacy and in an increased risk of psychotropic 
medication misuse. Based on these considerations, similarly to 
the other NPS, a growing consensus is being reached in consid-
ering non-pharmacological approaches as first-line treatments, 
limiting pharmacotherapies to non-responsive cases (35).
The studies that have so far explored the efficacy of non-
pharmacological and pharmacological interventions specifically 
targeting sundowning in dementia are described in Table  2. 
Isolated case reports and researches not explicitly focusing on the 
sundown syndrome (i.e., more broadly referring to sleep–wake 
disturbances, agitation, nocturnal behavioral disruptions) were 
not included in the table.
non-Pharmacological interventions
Individually tailored non-pharmacological approaches should 
be considered as the first-line therapy for sundowning. In par-
ticular, environmental modifications have been reported to be 
potentially beneficial to reduce sundown-related behavioral dis-
orders. Among these, light therapy (i.e., the exposition to bright 
light during the afternoon/evening hours) has been observed to 
produce a significant reduction of sundowning episodes (41) and 
motor restless behaviors (42) in open-label studies conducted on 
patients with dementia, as well as to improve agitated behaviors 
in institutionalized elderly individuals (43). Nevertheless, no 
RCT selectively investigating the efficacy of light therapy on 
sundowning has been yet conducted. Accordingly, in a recent 
Cochrane systematic review on the topic, authors concluded 
that there is insufficient evidence to justify the use of bright 
light therapy for improving cognition, activities of daily living, 
sleep, challenging behaviors, and psychiatric disturbances in 
dementia (44). Beside the lack of robust supporting evidence, 
ensuring a gradual transition from daylight to artificial lighting 
may attenuate behavioral changes occurring in the late afternoon 
and is commonly suggested by health-care providers. Additional 
recommendations may include minimizing unnecessary noise 
(e.g., noise from visitors, loud speakers, banging of dishes, loud 
staff conversation), promoting the adherence to schedules and 
stable daily routines, avoiding excessive sensory stimulation 
during the evening (both auditory and visual), discouraging 
afternoon napping, and planning more challenging activities 
(8, 18). Finally, other non-pharmacological strategies that have 
been shown to produce significant benefits in the management of 
NPS in patients with dementia (e.g., music therapy, aromatherapy, 
caregiver education, multisensory stimulation) may potentially 
be effective also in reducing sundowning.
Pharmacological interventions
Most of available evidences concerning the pharmacological 
management of sundowning have been focused on the clinical 
efficacy of melatonin supplementation (theoretically supported 
by the documented deregulation/reduction of melatonin pro-
duction in sundowners and in animal models). To date, only 
three RCTs have investigated the effectiveness of melatonin in 
reducing agitated behaviors in patients with dementia com-
pared to placebo, also reporting inconclusive and conflicting 
results (45–47). Nevertheless, these studies were not specifically 
designed to assess sundowning, while more widely investigat-
ing changes in sleep quality, overall daytime functioning and 
behavior. Thus, there is no available evidence coming from 
TAbLe 2 | experimental studies investigating the clinical effectiveness of pharmacological and non-pharmacological therapies for the management of 
sundowning in dementia.
Reference Study design Study sample intervention Assessment Main outcomes
Melatonin
Fainstein et al. (48) Open-label 41 elderly 
subjects (10 with 
Alzheimer’s disease 
(AD) and vascular 
dementia)
3 mg/day for 21 days Daily logs of sleep and 
wake quality completed 
by caregivers
Significant decrease of sundown agitation in the 70% 
of demented patients. Decrease of the coefficient of 
variation of bed time between days 0–2 and days 19–21 
of treatment (58.0 ± 24.7 vs 41.5 ± 20.9; p = 0.03) 
Brusco et al. (49)
Brusco et al. (49) Retrospective 14 outpatients with 
AD; mean MMSE 
score: 14.4 ± 7.9
9 mg/day for 
22–35 months
Daily logs of sleep and 
wake quality completed 
by caregivers
Remission of sundowning 12 patients; attenuation in two 
cases. Significant improvement of sleep quality between 
baseline and end of treatment (p < 0.01)
Cohen-Mansfield 
et al. (50)
Open-label 11 older nursing 
home residents 
with dementia
3 mg/day for 21 days Daily logs of sleep and 
wake quality completed 
by nurses, Cohen-
Mansfield Agitation 
Inventory
Significant reduction of sundown agitation between week 
1 and 4 (physically non-aggressive behavior: 1.92 vs 
1.46; p = 0.022. Verbally non-aggressive behavior: 2.30 
vs 1.75; p = 0.028)
Cardinali et al. (31) Open-label 45 outpatients 
with AD
6–9 mg/day for 
4 months
Daily logs of sleep and 
wake quality completed 
by caregivers
Suppression of sundowning (regardless of the 
concomitant medication employed to treat cognitive or 
behavioral signs of AD)
Mahlberg et al. (51) Open-label 7 AD outpatients 3 mg/day for 3 weeks Actigraphy Remission of sundowning in four patients; attenuation in 
two cases
Light therapy
Satlin et al. (41) Open-label 10 AD inpatients 2 h/day of exposure 
to bright light between 
7:00 and 9:00 p.m. for 
1 week
Clinical observation and 
actigraphy
Reduction of sundowning episodes 
Only studies specifically targeting sundowning were included in the table.
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ad hoc RCTs regarding the effects of melatonin supplementation 
in the treatment of sundowning in dementia. On the other hand, 
available open-label studies and case series (resumed in Table 2) 
have more consistently documented a reduction of sundowning 
episodes in most of patients with dementia receiving melatonin 
(31, 48–51). However, it should be noticed that some issues 
(e.g., influence of concomitant medications, severity of cogni-
tive decline, characteristics of the living environment) were not 
properly addressed and may have biased the study findings and 
conclusions.
Cholinesterase inhibitors have repeatedly been shown to 
produce a meaningful decrease of behavioral disturbances in 
demented patients (52). Conflicting data (mainly coming from 
isolated case reports) exist about their potential role in positively 
influencing sleep disorders, circadian rhythm alterations, and 
sundown behavioral disruptions occurring in AD and other 
dementias (53, 54). Currently, there is no specific data concern-
ing the treatment of sundowning with the N-methyl-d-aspartate 
receptor antagonist memantine.
Antipsychotics have been frequently indicated by physicians 
as the most commonly prescribed class of medications to man-
age sundowning (55). Nevertheless, there is limited information 
available in the medical literature on this particular topic, being 
most of RCTs focused on different NPS such as delusions, halluci-
nations, and agitation. Along the same lines, there is no evidence 
supporting the use of benzodiazepines and other hypnotics, 
whose use has been instead linked with a common paradoxical 
increase of behavioral disturbances.
COnCLUSiOn AnD FUTURe DiReCTiOnS
Sundowning represents a relevant and challenging manifesta-
tion of dementia, occurring in a large proportion of affected 
individuals and being associated with a significant social and 
economic burden. Increasing our knowledge on how to recog-
nize, approach, and manage sundowning may thus consent to 
significantly improve the wellbeing of patients and their carers. 
Specifically, a greater effort is needed in order to disentangle and 
clarify the complex and multifaceted pathophysiological bases of 
this phenomenon. Moreover, dedicated screening and assessment 
tools should be developed and validated in order to facilitate its 
detection in the routine clinical practice (particularly in outpatient 
settings). Finally, ad hoc RCTs should be designed and conducted 
to investigate the effectiveness of non-pharmacological- and 
pharmacological-targeted strategies for its management.
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